學術發表 - OBI Pharma 台灣浩鼎

Skip to content

關於我們
研發進展
新聞發佈
投資人專區
人力資源
永續發展
聯絡我們
English

關於我們
研發進展
新聞發佈
投資人專區
人力資源
永續發展
聯絡我們
English

學術發表

摘要海報文獻發表

抗體藥物複合體

前驅型藥物

抗體藥物複合體（ADC）

期刊	日期	類型	標題	延伸閱讀
JACS Au	2024/04/11	文獻發表	Structure-Based High-Efficiency Homogeneous Antibody Platform by Endoglycosidase Sz Provides Insights into Its Transglycosylation Mechanism	-
JCO Precision Oncology	2023/01/26	文獻發表	First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors	Globo H
Molecular Cancer Therapeutics	2021/06/01	文獻發表	Preclinical Studies of OBI-999: A Novel Globo H–Targeting Antibody–Drug Conjugate	Globo H

會議	日期	類型	標題	延伸閱讀
American Association for Cancer Research (AACR)	2024/04/10	摘要/海報	OBI-992, a novel TROP2 targeting antibody drug conjugate demonstrates superior in vivo PK/PD properties and a favorable safety profile	OBI-992
American Association for Cancer Research (AACR)	2024/04/08	摘要/海報	Development of a novel site-specific ADC glycan platform with potential for improved in vivo efficacy and stability of the ADC in animal studies	GlycOBI™
American Association for Cancer Research (AACR)	2024/04/08	摘要/海報	In vitro characterization of a novel TROP2-targeting antibody-drug conjugate OBI-992	OBI-992
American Association for Cancer Research (AACR)	2024/04/08	摘要/海報	OBI-992, a novel TROP2 targeting antibody-drug conjugate, displayed excellent antitumor efficacy in various animal models	OBI-992
American Association for Cancer Research (AACR)	2023/04/04	摘要/海報	OBI-999, an anti-Globo H antibody drug conjugate, exhibits synergistic anti-tumor effect in combination with pembrolizumab	Globo H
American Society of Clinical Oncology (ASCO)	2022/06/05	摘要/海報	First-in-Human Study of OBI-999: a Globo H-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors	Globo H
American Association for Cancer Research (AACR)	2021/04/10	摘要/海報	Preclinical characterization of a novel SSEA4-targeting antibody drug conjugate, OBI-998	-
American Society of Clinical Oncology (ASCO)	2020/05/29	摘要/海報	A Phase 1/2, Open‑Label, Dose-Escalation, and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI‑999 in Patients with Advanced Solid Tumors.	Globo H
American Association for Cancer Research (AACR)	2019/7/1	摘要/海報	Novel Globo H-targeting antibody-drug conjugate with binding specificity and anti-tumor efficacy in multiple cancer types	Globo H

疫苗

期刊	日期	類型	標題	延伸閱讀
Public Library of Science ONE	2023/03/24	文獻發表	Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies	-
Clinical/translational cancer immunotherapy	2022/06/22	文獻發表	The clinical relevance of humoral immune responses to Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 and expression of Globo H in metastatic breast cancer	Globo H, Adagloxad semolenin
Journal for ImmunoTherapy of Cancer	2020/07/22	文獻發表	Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study	Globo H, Adagloxad semolenin
Public Library of Science ONE	2017/06/08	文獻發表	Serum N-glycome characterization and anti-carbohydrate antibody profiling in oral squamous cell carcinoma patients	Globo H
Accounts of Chemical Research	2015/02/10	文獻發表	Development of Globo‑H Cancer Vaccines	Globo H, Adagloxad semolenin

會議	日期	類型	標題	延伸閱讀
American Society of Clinical Oncology (ASCO)	2022/6/6	摘要/海報	A phase 3, randomized, open-label study of the anti-Globo H vaccine Adagloxad Simolenin/OBI-821 in the adjuvant treatment of high-risk, early-stage, Globo H-positive triple-negative breast cancer	Globo H, Adagloxad semolenin
European Society for Medical Oncology (ESMO) Asia	2020/11/19	簡報	OBI-833 was safe and immunogenic, without treatment-related SAEs, in a phase I dose-escalation trial	Globo H, OBI-833
European Society for Medical Oncology (ESMO) Asia	2020/11/19	摘要/海報	A phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients	Globo H, OBI-833
American Society of Clinical Oncology (ASCO)	2020/5/29	摘要/海報	The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High Risk, Early-Stage, Globo H-Positive, Triple Negative Breast Cancer	Globo H, Adagloxad semolenin

前驅型藥物

期刊	日期	類型	標題	延伸閱讀
British Journal of Cancer	2023/05/12	文獻發表	Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, and clinical activity of OBI-3424 in patients with advanced or metastatic solid tumors	AKR1C3, OBI-3424
American Journal of Cancer Research	2021/07/15	文獻發表	A novel selective AKR1C3-activated prodrug AST-3424/OBI-3424 exhibits broad anti-tumor activity	AKR1C3, OBI-3424
Clinical Cancer Research	2019/07/15	文獻發表	OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL	AKR1C3, OBI-3424

會議	日期	類型	標題	延伸閱讀
American Society of Clinical Oncology (ASCO)	2022/06/02	摘要/海報	Safety, pharmacokinetics, and clinical activity of OBI-3424, an AKR1C3-activated prodrug, in patients with advanced or metastatic solid tumors: A phase 1 dose-escalation study.	AKR1C3, OBI-3424
American Association for Cancer Research (AACR)	2022/04/09	摘要/海報	OBI-3424, an AKR1C3-activated prodrug, exhibits in vivo synergistic anti-tumor effect in combination with pembrolizumab by induction of immunogenic cell death	AKR1C3, OBI-3424
American Association for Cancer Research (AACR)	2021/04/10	摘要/海報	Selective and Broad Anti-tumor Activity of AKR1C3-activated Prodrug AST-3424/OBI-3424	AKR1C3, OBI-3424
American Society of Clinical Oncology (ASCO)	2020/05/29	摘要/海報	A First-In-Man Phase 1/2 Study of OBI-3424, an AKR1C3-Selective Bis-Alkylating Agent Prodrug, in Subjects With Advanced Cancer, Including Hepatocellular Carcinoma (HCC) and Castrate-Resistant Prostate Cancer (CRPC)	AKR1C3, OBI-3424

其他

期刊	日期	類型	標題	延伸閱讀
American Journal of Cancer Research	2023/07/15	文獻發表	Investigation of the impact of Globo-H expression on the progression of gastric cancer	Globo H
Future Medicine	2021/11/04	文獻發表	The role of Globo H and SSEA-4 in the development and progression of cancer, and their potential as therapeutic targets	Globo H
Proceedings of the National Academy of Sciences	2019/02/11	文獻發表	Signaling pathway of globo-series glycosphingolipids and β1,3-galactosyltransferase V (β3GalT5) in breast cancer	Globo H

會議	日期	類型	標題	延伸閱讀
American Association for Cancer Research (AACR)	2023/04/04	摘要/海報	Globo H-Targeted CAR T Cell Cancer Immunotherapy	Globo H
American Association for Cancer Research (AACR)	2022/04/09	摘要/海報	High Globo-H expression associated with poor survival of gastric cancer patients and enriched PD-L1 expression	Globo H
American Association for Cancer Research (AACR)	2021/04/10	摘要/海報	Inhibitory activity of Globo-H and SSEA-4 on activated T cells	Globo H
American Association for Cancer Research (AACR)	2019/07/01	摘要/海報	Anti-tumor efficacy and potential mechanism of action of a novel therapeutic humanized anti-Globo H antibody, OBI-888	Globo H
American Association for Cancer Research (AACR)	2019/07/01	摘要/海報	Specificity, biodistribution, tumor targeting, and pharmacokinetics of a novel humanized anti-Globo H antibody, OBI-888, for cancer immunotherapy	Globo H

公司簡介

經營團隊

永續發展

研發進展

新聞發佈

投資總覽

人力資源

聯絡我們

隱私權政策

© 2020 OBI Pharma.Web Development by 展躍設計

我們使用Cookies, 如您繼續使用我們的網站表示您接受我們的隱私權政策和cookies的使用。

Cookie設定我接受

Manage consent

必要性

Always Enabled

必要性cookies在網站內是絕對重要的功能, 此分類僅包含功能性及安全性的cookies, 此cookies不會存取任何個人隱私資料。

非必要性

任何對於網站潛在必要性的cookies已經使用, 非必要性則為收集個資, 數據, 廣告置入等..

SAVE & ACCEPT